Last Day
Drug Manufacturers – General
Latest Valuation
- Trailing PE:
- Forward PE:
- Price Sales TTM:
- Price Book MRQ:
- Enterprise Value:
- Enterprise Value Revenue:
- Enterprise Value Ebitda:
- Beta:
Key Highlights
- Shares Outstanding:
- Market Capitalization:
- Market Capitalization Mln:
- EBITDA:
- PE Ratio:
- PEG Ratio:
- Wall Street Target Price:
- Book Value:
- Dividend Share:
- Dividend Yield:
- Earnings Share:
- EPS Estimate Current Year:
- EPS Estimate Next Year:
- EPS Estimate Next Quarter:
- EPS Estimate Current Quarter:
- Most Recent Quarter:
- Profit Margin:
- Operating Margin TTM:
- Return On Assets TTM:
- Return On Equity TTM:
- Revenue TTM:
- Revenue Per Share TTM:
- Quarterly Revenue Growth YOY:
- Gross Profit TTM:
- Diluted Eps TTM:
- Quarterly Earnings Growth YOY:
Basic Information
- Type:
- Name:
- Exchange:
- Currency Code:
- Currency Name:
- Currency Symbol:
- Country Name:
- Fiscal Year End:
- IPO Date:
- International Domestic:
- Sector:
- Industry:
- Address:
- Country:
- Listings:
- Web URL:
- Full Time Employees:
- Updated At:
- Gic Sector:
- Gic Group:
- Gic Industry:
- Gic SubIndustry:
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. Address: Route 206 & Province Line Road, Princeton, NJ, United States, 08543